A new risk: Kidney Cancer
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
While it's great to hear of new benefits of using GLP1 Receptor Agonists every few days or weeks, it's equally (if not more) important to hear about new negative side effects (with or without evidence).
🍃
Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?
Check out our quick explainer
Check out our quick explainer
We've reported on the negative side effects on before (and try to do so regularly):
Are GLP1 side effects all the same?
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let’s look at the research.
GLP1.Guide Staff
Recently there have been reports of a possible new negative side effect of taking GLP1s – kidney cancer.
As is often the case, financial markets are first to start sharing this widely:
What’s Going On With Novo Nordisk Shares Today? - Novo Nordisk (NYSE:NVO)
Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney cancer.
Vaishali Prayag
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
